Table S1. The distribution of IDH, MGMT and 1p19q in glioma.
| Patient characteristics | IDH mut n=122 (%) | IDH wild n=185 (%) | MGMT met, n=130 (%) | MGMT unmet, n=178 (%) | 1p19q codel, n=100 (%) | 1p19q uncodel, n=354 (%) |
|---|---|---|---|---|---|---|
| Sex | ||||||
| Male | 72 (59.0) | 113 (61.1) | 79 (60.7) | 108 (60.7) | 60 (60.0) | 206 (58.2) |
| Female | 50 (41.0) | 72 (38.9) | 51 (39.3) | 70 (39.3) | 40 (40.0) | 148 (41.8) |
| Age | ||||||
| Median [range] | 45 (22–69] | 44 [1–80] | 48 [4–69] | 40 [1–80] | 48 [27–71] | 42 [1–80] |
| Grades | ||||||
| I/II | 62 (50.8)* | 53 (28.6) | 50 (38.5) | 65 (38.5) | 64 (64.0)* | 141 (39.8) |
| III/IV | 60 (49.2) | 132 (71.4) | 80 (61.5) | 113 (63.5) | 36 (36.0) | 213 (60.2) |
| Histology | ||||||
| Glioblastoma | 24 (19.7) | 87 (47.0) | 44 (33.8) | 67 (38.5) | 7 (7.0) | 123 (34.7) |
| Diffuse midline glioma | 0 (0) | 14 (7.6) | 2 (1.5) | 12 (6.7) | 1 (1.0) | 13 (3.7) |
| Medulloblastoma | 0 (0) | 1 (0.5) | 0 (0) | 1 (0.6) | 0 (0) | 2 (0.6) |
| Anaplastic astrocytoma | 25 (20.5) | 30 (16.2) | 24 (18.5) | 32 (18.0) | 7 (7.0) | 65 (18.4) |
| Anaplastic Oigodendroglioma/oligoastrocytoma | 11 (9.0) | 1 (0.5) | 11 (8.5) | 1 (0.6) | 20 (20.0) | 11 (3.1) |
| Astrocytoma | 42 (34.4) | 35 (18.9) | 29 (22.3) | 49 (27.5) | 12 (12.0) | 96 (27.1) |
| Oligodendroglioma/oligoastrocytoma | 19 (15.6) | 5 (2.7) | 19 (14.6) | 4 (2.2) | 52 (52.0) | 27 (7.6) |
| Ganglioglioma | 0 (0) | 2 (1.1) | 0 (0) | 2 (1.1) | 1 (1.0) | 3 (0.8) |
| Subependymal giant cell astrocytoma | 1 (0.8) | 0 (0) | 0 (0) | 1 (0.6) | 0 (0) | 1 (0.3) |
| Pilocytic astrocytoma | 0 (0) | 10 (5.4) | 1 (0.8) | 9 (5.1) | 0 (0) | 13 (3.7) |
*, P<0.05. IDH, isocitrate dehydrogenase; MGMT, O-6-methylguanine-DNA methyltransferase.